Evaluation and treatment of inflammatory myopathies

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 80, Issue 10, 2009, Pages 1060-1068

  Amato, A A ^a   Barohn, R J ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; FRUCTOSE BISPHOSPHATE ALDOLASE; IMMUNOGLOBULIN; INFLIXIMAB; LACTATE DEHYDROGENASE; MEPREDNISONE; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYOGLOBIN; PREDNISONE; RITUXIMAB; TACROLIMUS; VITAMIN D;

ALOPECIA; AMBLYOPIA; ANAPHYLAXIS; ANXIETY; ASEPTIC MENINGITIS; ASEPTIC NECROSIS; BONE MARROW SUPPRESSION; CATARACT; CELL INFILTRATION; CLINICAL EXAMINATION; CLINICAL TRIAL; COLONOSCOPY; CONFUSION; COUGHING; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DIAPHORESIS; DIARRHEA; DISEASE ASSOCIATION; DRUG MEGADOSE; DYSGEUSIA; ELECTROCARDIOGRAM; ELECTROMYOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FLU LIKE SYNDROME; GINGIVA HYPERPLASIA; HEADACHE; HEART ARRHYTHMIA; HEMORRHAGIC CYSTITIS; HIRSUTISM; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INCLUSION BODY MYOSITIS; INFECTION; INFERTILITY; INSOMNIA; LEUKOPENIA; LIVER TOXICITY; LUNG FIBROSIS; MEGALOCYTOSIS; MORNING DOSAGE; MOTOR UNIT POTENTIAL; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOSITIS; NAUSEA; NECROTISING MYOPATHY; NEOPLASM; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OSTEOPOROSIS; PANCREATITIS; PHYSICAL EXAMINATION; PLASMAPHERESIS; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; STOMACH IRRITATION; STOMATITIS; STROKE; TERATOGENICITY; THYMECTOMY; TREMOR; VOMITING; WHOLE BODY RADIATION;

ANTI-INFLAMMATORY AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOSITIS; RISK FACTORS;

EID: 70349673434     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.169375     Document Type: Review

References (108)

1. Amato AA, Russell J. Neuromuscular disease. New York: McGraw-Hill, 2008:681-719.
2. Amato AA, Barohn RJ. Idiopathic inflammatory myopathies. Neurol Clin 1997;15:615-648
3. Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol 2004;17:561-567
4. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705-713
5. Hoogendijk JE, Amato AA, Lecky BR, et al. Workshop report. 119th ENMC international workshop: Trial; design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromusc Dis 2004;14:337-345
6. Grable-Esposito P, Katzberg HD, Greenberg SA, et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve (in press).
7. Vosskamper M, Korf B, Franke B, et al. Paraneoplastic necrotizing myopathy: a rare disorder to be differentiated form polymyositis. J Neurol 1989;236:489-490 (Pubitemid 20019438)
8. Bronner IM, Hoogendijk JE, Wintzen AR, et al. Necrotizing myopathy, an unusual presentation of a steroid responsive myopathy. J Neurol 2003;250:480-485 (Pubitemid 36459756)
9. Sadeh M, Dabby R. Steroid-responsive myopathy: immune-mediated necrotizing myopathy or polymyositis without inflammation? J Clin Neuromuscul Dis 2008;9:341-344
10. Needham M, Fabian V, Knezevic W, et al. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Dis 2007;17:194-200. (Pubitemid 46274372)
11. Emslie-Smith AM, Engel AG. Necrotizing myopathy with pipestem capillaries, microvascular deposition of complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology 1991;41:936-939
12. Sigurgeirsson B, Lindelöf B, Edhag O, et al. Risk of cancer in patient with dermatomyositis or polymyositis. N Engl J Med 1992;326:363-367
13. Callen JP. Relationship of cancer to inflammatory muscle diseases: Dermatomyositis, polymyositis, and inclusion body myositis. Rheum Dis Clin N Am 1994;20:943-953
14. Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry 2009 (in press) (doi: 10.1136/jnnp.2009.173823).
15. Hochberg MC, Feldman D, Stevens MB. Adult-onset polymyositis/ dermatomyositis: Analysis of clinical and laboratory features and survival in 76 cases with a review of the literature. Semin Arthritis Rheum 1986;15:168-178 (Pubitemid 16132225)
16. Sontheimer RD. Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol 1999;11:475-482
17. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis: a review. J Invest Dermatol 1993;100:124S-7.
18. Cohen MG, Nash P, Webb J. Calcification is rare in adult-onset dermatomyositis. Clin Rheumatol 1986;5:512-516
19. Pachman LM. Juvenile dermatomyositis: immunogenetics, pathophysiology, and disease expression. Rheum Dis Clin North Am 2002;28:579-602.
20. Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain 1989;112:727-747
21. Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: Clinical and pathological boundaries. Ann Neurol 1996;40:581-586 (Pubitemid 26357882)
22. Bohan A, Peter JB, Bowman RL, et al. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977;56:255-286 (Pubitemid 8130612)
23. Tymms KE, Webb J. Dermatomyositis and other connective tissue diseases: A review of 105 cases. J Rheumatol 1985;12:1140-1148 (Pubitemid 16166460)
24. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991;70:360-374
25. Hochberg MC, Feldman D, Stevens MB, et al. Antibody to Jo-1 in polymyositis/ dermatomyositis: association with interstitial pulmonary disease. J Rheumatol 1984;11:663-665 (Pubitemid 15215055)
26. Hengstman GJ, Brouwer R, Egberts WT, et al. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 2002;249:69-75. (Pubitemid 34119026)
27. Hengstman GJ, van Engelen BG, van Venrooij WJ. Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr Opin Rheumatol 2004;16:692-699
28. Hengstman GJ, ter Laak HJ, Vree Egberts WT, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006;65:1635-1638
29. Miller T, Al-Lozi MT, Lopate G, et al. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002;73:420-428
30. Fraser DD, Frank JA, Dalakas M, et al. Magnetic resonance imaging in idiopathic inflammatory myopathies. J Rheumatol 1991;18:1693-1700
31. Hernandez RJ, Sullivan DB, Chenevert TL, et al. MR imaging in children with dermatomyositis: Findings and correlations with clinical and laboratory findings. AJR Am J Roentgenol 1993;161:359-366
32. Pitt AM, Fleckenstein JL, Greenlee RG Jr, et al. MRI-guided biopsy in inflammatory myopathy: Initial results. Magn Reson Imaging 1993;11:1093-1099 (Pubitemid 23333713)
33. Amato AA, Dumitru D. Acquired myopathies. In: Dumitru D, Amato AA, Swartz MJ, eds. Electrodiagnostic medicine, 2nd Edn. Philadelphia: Hanley & Belfus, 2002:1265-1432
34. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I. Quantitative of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984;16:193-208.
35. Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984;16:209-215
36. Greenberg SA, Jack L, Pinkus JL, et al. Interferon-a/b mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664-678 (Pubitemid 40628855)
37. Greenberg SA, Sanoudou D, Haslett JN, et al. Molecular profiles of the inflammatory myopathies. Neurology 2002;59:1170-1182
38. Walsh RJ, Kong SW, Yao Y, et al. Type 1 interferon-inducible blood gene expression is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007;56:3784-3792 (Pubitemid 350100711)
39. Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007;69:2008-2019
40. Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex 1 antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989;20:224-231 (Pubitemid 19081957)
41. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-982
42. van der Meulen MF, Bronner IM, Hoogendijk JE, et al. Polymyositis: an overdiagnosed entity. Neurology 2003;61:316-321
43. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008;70:418-424
44. Hengstman GJ, van Engelen BG. Polymyositis, invasion of non-necrotic muscle fibres, and the art of repetition. BMJ 2004;329:1464-1467
45. Greenberg SA, Bradshaw EM, Pinkus JL, et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005;65:1782-1787
46. Bradshaw EM, Orihuela A, McArdel SL, et al. A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 2007;178:547-556 (Pubitemid 46033639)
47. Greenberg SA, Pinkus GS, Amato AA, et al. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 2007;35:17-23. (Pubitemid 46052644)
48. Bunch TW, Worthington JW, Combs JJ, et al. Azathioprine with prednisone for polymyositis. Ann Intern Med 1980;92:365-369
49. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000. (Pubitemid 24015043)
50. Muscle Study Group. A randomized trial of bINF1a (Avonex) in patients with inclusion body myositis (IBM). Neurology 2001;57:1566-1570
51. Muscle Study Group. Randomized pilot trial of high dose βINF1a in patients with inclusion body myositis. Neurology 2004;63:718-720
52. Dalakas MC, Sonies B, Dambrosia, et al. Treatment of inclusion body myositis with IVIg: A double-blind, placebo-controlled study. Neurology 1997;48:712-716 (Pubitemid 27120112)
53. Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001;56:323-327 (Pubitemid 32144142)
54. Badsrising UA, Maat-Schieman MLC, Ferrari MD, et al. Comparison of weakness progression in inclusion body myositis duuring treatment with methotrexate or placebo. Ann Neurol 2002;51:369-372
55. Greenberg SA, Amato AA. Inflammatory myopathy associated with mixed connective tissue disease and scleroderma renal crisis. Muscle Nerve 2001;4:1562-1566
56. Cagnoli M, Marchesoni A, Tosi S. Combined steroid, methotrexate, and chlorambucil therapy for steroid resistant dermatomyositis. Clin Exp Rheumatol 1991;9:658-659
57. Giannini M, Callen JP. Treatment of dermatomyositis with methotrexate and prednisone. Arch Dermatol 1979;115:1251-1252
58. Metzger AL, Bohan A, Goldberg LS, et al. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med 1974;81:182-189
59. Sokoloff MC, Goldberg LS, Pearson CM. Treatment of corticosteroid- resistant polymyositis with methotrexate. Lancet 1971;1:14-16.
60. Miller LC, Sisson BA, Tucker LB, et al. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum 1992;35:1143-1149
61. Joffe MM, Love LA, Leff RL, et al. Drug therapy of idiopathic inflammatory myopathies: Predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993;94:379-387
62. Bunch TW. Prednisone and azathioprine for polymyositis: Long-term follow-up. Arthritis Rheum 1981;24:45-48
63. Kissel JT, Levy RJ, Mendell JR, et al. Azathioprine toxicity in neuromuscular disease. Neurology 1986;36:35-39
64. Majithia V, Harisdangkul V. Mycophenolate mofetil (Cellcept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology 2005;44:386-389 (Pubitemid 40361299)
65. Schneider C, Gold R, Schafers M, et al. Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve 2002;25:286-288 (Pubitemid 34117079)
66. Tausche AK, Meurer M. Mycophenolate mofetil for dermatomyositis. Dermatology 2001;202:341-343
67. Rowin J, Amato AA, Dresisher N, et al. Mycophenolate mofetil in dermatomyositis. Is it safe? Neurology 2006;66:1245-1247
68. Borleffs JC. Cyclosporine as monotherapy for polmyositis? Transplant Proc 1988;20:333-334
69. Correia O, Polonia J, Nunes JP, et al. Severe acute form of adult dermatomyositis treated with cyclosporine. Int J Dermatol 1992;31:517-519
70. Girardin E, Drayer JM, Paunier L. Cyclosporine for juvenile dermatomyositis. J Pediatr 1988;112:165-166
71. Goei HS, Jacobs P, Hoeben H. Cyclosporine in the treatment of intractable polymyositis. Arthritis Rheum 1985;28:1436-1437
72. Heckmatt J, Hasson N, Saunders C, et al. Cyclosporine in juvenile dermatomyositis. Lancet 1989;1:1063-1066
73. Jones DW, Snaith ML, Isenberg DA. Cyclosporine treatment for intractable polymyositis. Arthritis Rheum 1987;30:959-960
74. Lueck CJ, Trend P, Swash M. Cyclosporine in the management of polymyositis and dermatomyositis. J Neurol Neurosurg and Psychiatry 1991;54:1007-1008
75. Mehregan AL, Su WPD. Cyclosporine treatment for dermatomyositis/ polymyositis. Cutis 1993;51:59-61.
76. Pistoia V, Buoncompagni A, Scribanis R, et al. Cyclopsorin A in the treatment of juvenile chronic arthritis and childhood polymyositis- dermatomyositis: Results of a preliminary study. Clin Exp Rheumatol 1993;11:203-208 (Pubitemid 23155993)
77. Oddis CV, Sciurba FC, Elmagd KA, et al. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999;353:1762-1763 (Pubitemid 29240378)
78. Hassan J, van der Net JJ, van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol 2008;27:1469-1471
79. Mitsui T, Kuroda Y, Kunishige M, et al. Successful treatment with tacrolimus in a case of refractory dermatomyositis. Intern Med 2005;44:1197-1199
80. Kono DW, Klashman DJ, Gilbert RC. Successful IV pulsed cyclophosphamide in refractory PM in 3 patients with SLE. J Rheumatol 1990;17:982-983
81. Leroy JP, Drosos AA, Yiannopoulos DI, et al. Intravenous pulse cyclophosphamide therapy in myositis and Sjögren's syndrome. Arthritis Rheum 1990;33:1579-1581 (Pubitemid 20362103)
82. Niakan E, Pitner SE, Whitaker JN, et al. Immunosuppressive agents in corticosteroid-refractory childhood dermatomyositis. Neurology 1980;30:286-291 (Pubitemid 10133764)
83. Cronin ME, Miller FW, Hicks JE, et al. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 1989;16:1225-1228 (Pubitemid 19260112)
84. Fries JF, Sharp GC, McDevitt HO, et al. Cyclophosphamide therapy in systemic lupus erythematosis and polymyositis. Arthritis Rheum 1973;16:154-162
85. Hengstman GJ, van den Hoogen FH, Barrera P, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 2003;50:10-15. (Pubitemid 36736963)
86. Hengstman GJD, van den Hoogen FHJ, van Engelen BGM. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-: long-term follow-up. Eur Neurol 2004;52:61-63 (Pubitemid 39077819)
87. Labioche I, Liozon E, Weschler B, et al. Refractory polymyositis responding to infliximab: extended follow-up. Rheumatology 2004;43:531-532 (Pubitemid 38489380)
88. Korkmaz C, Temiz G, Cetinibas F, et al. Case report: successful treatment of alveolar hypoventilation due to DM with anti-tumor necrosis factor-alpha. Rheumatology 2004;43:937-938 (Pubitemid 38996975)
89. Sprott H, Glatzel M, Michel BA. Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology 2004;43:524-526 (Pubitemid 38489376)
90. Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006;65:1233-1236 (Pubitemid 44277404)
91. Riley P, McCann LJ, Maillard SM, et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology 2008;47:877-880 (Pubitemid 351796377)
92. Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008;67:1670-1677
93. Hengstman GJ, De Bleecker JL, Feist E, et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008;59:159-163 (Pubitemid 351301260)
94. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005;52:601-607 (Pubitemid 40216325)
95. Cooper MA, Willingham DL, Brown DE, et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007;56:3107-3111 (Pubitemid 47502758)
96. Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 2007;34:1864-1868 (Pubitemid 350067647)
97. Brewer EJ, Giannini EH, Rossen RD, et al. Plasma exchange therapy of a childhood onset dermatomyositis patient. Arthritis Rheum 1980;23:509-513
98. Dau PC. Plasmapheresis in idiopathic inflammatory myopathy. Arch Neurol 1981;38:544-552
99. Herson S, Cherin P, Coutellier A. The association of plasma exchange synchronized with intravenous gamma globulin therapy in severe intractable polymyositis. J Rheumatol 1992;19:828-829
100. Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukopheresis in polymyositis and dermatomyositis. N Engl J Med 1992;326:1380-1384
101. Hubbard WN, Walport MJ, Halnan KE, et al. Remission from polymyositis after total body irradiation. BMJ 1982;284:1915-1916
102. Kelly JJ, Madoc-Jones H, Adelman LS, et al. Response to total body irradiation in dermatomyositis. Muscle Nerve 1988;11:120-123 (Pubitemid 18039610)
103. Morgan SH, Bernstein RM, Coppen J. Total body irradiation and the course of polymyositis. Arthritis Rheum 1985;28:831-835 (Pubitemid 15027340)
104. Cherin P, Herson S, Coutellier A, et al. Failure of total body irradiation in polymyositis: report of three cases. Br J Rheumatol 1992;31:282-283
105. Kelly JJ, Madoc-Jones H, Adelman LS, et al. Total body irradiation not effective in inclusion body myositis. Neurology 1986;36:1264-1266 (Pubitemid 16047014)
106. Cumming WJK. Thymectomy in refractory dermatomyositis. Muscle Nerve 1989;12:424.
107. Greenberg SA. Inclusion body myositis: review of recent literature. Curr Neurol Neurosci Rep 2009;9:83-89
108. Greenberg SA. How citation distortions create unfounded authority: analysis of a citation network. BMJ 2009;339:62680.